FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Atrys Health's Free Cash Flow for the
six
months ended in Dec. 2025 was €-11.0 Mil. Atrys Health's Revenue for the
six
months ended in Dec. 2025 was €69.9 Mil. Therefore, Atrys Health's FCF Margin % for the quarter that ended in Dec. 2025 was -15.76%.
The historical rank and industry rank for Atrys Health's FCF Margin % or its related term are showing as below:
XMAD:ATRY'
s FCF Margin % Range Over the Past 10 Years
Min: -52.18 Med: -19.08 Max: -3.2
Current: -7.58
During the past 10 years, the highest FCF Margin % of Atrys Health was -3.20%. The lowest was -52.18%. And the median was -19.08%.
XMAD:ATRY's FCF Margin % is ranked better than 69.58% of 960
companies
in the Biotechnology industry
Industry Median: -85.21
vs XMAD:ATRY: -7.58
Atrys Health FCF Margin % Related Terms
Atrys Health FCF Margin % Historical Data
* Premium members only.
The historical data trend for Atrys Health's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XMAD:ATRY vs VRTX, REGN, ALNY: FCF Margin % Comparison
For the Biotechnology subindustry, Atrys Health's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrys Health FCF Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrys Health's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Atrys Health's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Atrys Health (XMAD:ATRY) has a FCF Margin % of -15.76% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #292 out of 960 companies in the Biotechnology industry, placing it in the top 30.4%.
Is Atrys Health's FCF Margin % too high?
Atrys Health's current FCF Margin % is -15.76%. Based on the distribution chart, Atrys Health ranks #292 out of 960 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #292 out of 960 companies for FCF Margin %. This puts Atrys Health in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Atrys Health and its competitors. Atrys Health's current FCF Margin % is -15.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.11, compared to a current price of €2.57 — trading 17.5% below its estimated fair value. The current FCF Margin % is -15.76%. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current FCF Margin % is -15.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Atrys Health (XMAD:ATRY) Overvalued in 2026?
Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued.
The current stock price of €2.57 is trading 17.5% below its estimated GF Value™ of €3.11.
GuruFocus considers Atrys Health to be Modestly Undervalued.
Key valuation signals for XMAD:ATRY:
FCF Margin %: -15.76%
GF Value™: €3.11 vs. price of €2.57 (17.5% below fair value)
No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score
Get the complete analysis for XMAD:ATRY
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XMAD:ATRY has been successfully added to your 
